Immunic, Inc. to Participate in Investor Conferences in December

Immu-SI Press Release

NEW YORK, November 24, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management’s participation in the following investor conferences in December: November 30 – December 3: Piper Sandler 32nd Virtual Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, …

Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board

Immu-SI Press Release

– Initial Appointments Include Internationally Recognized Experts: Fred D. Lublin, M.D.; Bruce E. Sands, M.D., M.S.; Jerrold R. Turner, M.D., Ph.D. and Paul J. Utz, M.D. – NEW YORK, November 17, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the formation of …

Immunic, Inc. to Participate in Investor and Scientific Conferences in November

Immu-SI Press Release

NEW YORK, November 10, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management’s participation in the following investor and scientific conferences in November: November 16-18: Stifel 2020 Virtual Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present …

Immunic, Inc. Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Immu-SI Press Release

– Released Very Positive Phase 2 Data for IMU-838 in Relapsing-Remitting Multiple Sclerosis; Company to Submit End-of-Phase 2 Meeting Requests to Regulatory Authorities at the End of Q1 2021 – – 200 Patients Randomized in Phase 2 Trial of IMU-838 for the Treatment of Moderate COVID-19; Top-Line Data From Main Phase 2 Efficacy Analysis Expected in Q1 2021 – – …

Immunic, Inc. Announces 200 Patients Enrolled in Its Phase 2 CALVID-1 Trial of IMU-838 for the Treatment of Moderate COVID-19, Allowing for Main Phase 2 Efficacy Analysis to Proceed

Immu-SI Press Release

– Top-Line Data Expected in Q1 2021 – NEW YORK, November 2, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that the company has enrolled and randomized 200 patients, pre-specified in the protocol as sufficient to perform the main efficacy analysis of …

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

Immu-SI Press Release

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy European Investment Bank and Immunic sign a financing agreement of up to €24.5 million to support the development of Immunic’s lead asset, IMU-838, in moderate COVID-19 IMU-838 is an orally available small molecule, which, because of its broad-spectrum antiviral effect and selective immunomodulatory …

Immunic, Inc. to Participate in Scientific Conferences in October

Immu-SI Press Release

NEW YORK, September 29, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific conferences in October: October 6-7: BioNJ’s 10th Annual BioPartnering Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present a company overview …

Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19

Immu-SI Press Release

NEW YORK, September 28, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the results of a pre-planned interim safety analysis and a recruitment update from the ongoing phase 2 CALVID-1 trial of its selective oral DHODH inhibitor, IMU-838, in patients with moderate …

Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020

IMMU_TH Press Release

– Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations – – Time Course of MRI Lesion Suppression Shows Reduction of Lesions Already Present at First Post-Baseline Scan at Week 6, Validating Rapid Attainment of Stable Therapeutic Drug Levels of IMU-838 – – A Robust Decrease in Serum Neurofilament Light Chain, A Biomarker for Axonal Damage, Was Observed in Both …

Immunic, Inc. to Participate in Scientific and Investor Conferences in September

IMMU_TH Press Release

NEW YORK, September 8, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in September: September 11-13: MSVirtual2020 / 8th Joint ACTRIMS-ECTRIMS Meeting. Robert J. Fox, MD, Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio, …